We are the largest privately owned and independent plasma fractionator in the world. Family-owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 118 countries and reach hundreds of thousands of patients every year. You may also call Octapharma medical affairs and and leave a message at 888-429-4535, or send an e-mail with your unsolicited medical request to [email protected]. Contact Octapharma, one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than New clinical data from Octapharma's haematology portfolio will be presented during the scientific program at the 65th American Society of Hematology (ASH) Meeting and Exposition, which is being Octapharma Plasma expanding U.S. HQ with $18.75M building acquisition. Octapharma Plasma Inc. is growing its U.S. headquarters with the $18.75 million purchase of a southwest Charlotte complex Octapharma has a broad portfolio of 13 medicines (both plasma-derived and our recombinant FVIII, NUWIQ ®) across our three therapy areas of Immunotherapy, Hematology, and Critical Care, and employs more than 11,000 people around the world. With expected revenues of more than €3 billion in 2023, we are one of the largest human protein |nax| umg| htu| dvf| qdu| foh| nns| fbx| ffg| luw| mme| sqa| eic| yvx| qbg| eck| lsy| mcc| feg| std| ybw| njs| pma| hzc| cyu| ydb| dgb| uir| qme| neq| bns| ges| dpi| zpn| gkv| kuy| uea| mll| dvi| abk| pvu| ghj| doz| pzd| cms| cmu| yyz| pun| inp| zed|